Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.37 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198350 | 0.90 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL18503451 | 0.82 | P2RY2 (0.56) | P2RY2P2RY4P2RY6 | |
| SCHEMBL18503499 | 0.81 | NT5E (0.42) | TDP1P2RY14P2RY2P2RY4NT5E | |
| SCHEMBL18503494 | 0.81 | NT5E (0.42) | TDP1P2RY14P2RY2P2RY4NT5E | |
| SCHEMBL29323315 | 0.81 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL12408824 | 0.78 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL21490243 | 0.76 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL19987163 | 0.76 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL19987242 | 0.76 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL31201425 | 0.74 | SLC28A1 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | SLC28A1 82/4885SLC28A2 32/4885SLC29A1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.